BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akhmetzhanov AR, Kim JW, Sullivan R, Beckman RA, Tamayo P, Yeang C. Modelling bistable tumour population dynamics to design effective treatment strategies. Journal of Theoretical Biology 2019;474:88-102. [DOI: 10.1016/j.jtbi.2019.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ilan Y, Spigelman Z. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance. Cancer Treatment and Research Communications 2020;25:100240. [DOI: 10.1016/j.ctarc.2020.100240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Beckman RA, Kareva I, Adler FR. How Should Cancer Models Be Constructed? Cancer Control 2020;27:1073274820962008. [PMID: 32991214 DOI: 10.1177/1073274820962008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kareva I, Luddy KA, O'Farrelly C, Gatenby RA, Brown JS. Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One? Front Immunol 2021;12:668221. [PMID: 34531851 DOI: 10.3389/fimmu.2021.668221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Clarke MA, Fisher J. Executable cancer models: successes and challenges. Nat Rev Cancer 2020;20:343-54. [PMID: 32341552 DOI: 10.1038/s41568-020-0258-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]